Innovative Immune Monitoring Immudex specializes in advanced immune monitoring technologies such as Dextramer® reagents, enabling detection of antigen-specific immune cells, which is highly valuable for biotech and pharma companies involved in immunotherapy development and immune response research.

Expanding Product Portfolio The recent launch of products like U-Load Dextramer® and dCODE reagents demonstrates their commitment to providing versatile tools for immune cell analysis, presenting opportunities to upsell or cross-sell alongside existing products and attract new research partnerships.

Collaborative Growth Strategic collaborations with prominent organizations like BD and 10x Genomics highlight Immudex's capacity to integrate with leading systems, creating potential for joint sales efforts and integrated solution offerings targeting high-throughput sequencing and single-cell analysis markets.

Market Focus Areas Operating within the biotechnology research sector in Denmark and beyond, Immudex is positioned to serve clients in immunology, cancer research, and vaccine development, offering tailored solutions that can meet evolving demands in precision immune monitoring.

Moderate Financial Capacity With revenue estimates between 1 million to 10 million dollars, Immudex presents an attractive opportunity for scaled investment or partnership as it seeks to expand its market reach and product adoption in the competitive immune research landscape.